EUVIMEDEUVIMED entdecken
Crossref

Recurrent Pleomorphic Adenoma of the Parotid Gland: Proposal for an LMCG Classification System and an Optimized Therapeutic Algorithm

Qicheng Ye, Dongrui Liu, Lingli Huang, Wenya Zhu, Hao Lu, Wenjun Yang, Wanlin Xu iD

Oral Diseases · 2025

DOI: 10.1111/odi.70022 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oral Diseases, 2025. Verfasst von Qicheng Ye und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, Coll…. Hauptthemen laut MEDLINE: Adenoma, Pleomorphic, Parotid Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Biobank Project of Shanghai Ninth People's Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To introduce a novel clinical classification system and corresponding therapeutic strategies for parotid recurrent pleomorphic adenoma (RPA).

Methods

A retrospective analysis was conducted on parotid RPA cases treated by a single surgical team at Shanghai Ninth People's Hospital between January 2020 and December 2024. Based on tumor features—such as single or multiple nodules, infringement of adjacent structures, or skip metastases—as well as intraoperative facial nerve status, a classification system and corresponding treatment strategy were proposed.

Results

A total of 66 patients were included in the study. The majority (95.5%) presented with multinodular tumors, and 66.7% developed facial paralysis due to intraoperative facial nerve injury. The classification system termed “Localized–Moderate–Complicated–General” (LMCG) was first developed. The Localized type represents the least severe condition, while the subsequent categories reflect progressively more complex presentations. Each classification corresponds to a tailored therapeutic strategy, ranging from partial parotidectomy with or without facial nerve preservation to extensive parotidectomy combined with immediate nerve reconstruction and adjuvant radiotherapy.

Conclusion

The LMCG classification offers a concise framework for preoperative assessment and personalized treatment planning in patients with parotid RPA, with the potential to standardize and improve its clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenoma, PleomorphicParotid NeoplasmsNeoplasm Recurrence, LocalHumansRetrospective StudiesMaleFemaleMiddle AgedAdultAlgorithmsAgedFacial Nerve InjuriesParotid GlandFacial ParalysisYoung Adult

Stichwörter der Autor:innen

clinical classificationparotid tumorrecurrent pleomorphic adenomasalivary gland tumor

Autor:innen und Institutionen

  • Department of Oral and Maxillofacial-Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine, College of Stomatology, Shanghai Jiao Tong University, National Center for…
  • Department of Stomatology, Fengcheng Hospital, Fengxian District, Shanghai, China.
  • Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu, China.

ORCID-Profile: Wanlin Xu

Förderung

  • Biobank Project of Shanghai Ninth People's Hospital

Zitieren

APA

Ye, Q., Liu, D., Huang, L., Zhu, W., Lu, H., Yang, W., & Xu, W. (2025). Recurrent Pleomorphic Adenoma of the Parotid Gland: Proposal for an LMCG Classification System and an Optimized Therapeutic Algorithm. Oral Diseases. https://doi.org/10.1111/odi.70022

Vancouver

Ye Q, Liu D, Huang L, Zhu W, Lu H, Yang W, et al. Recurrent Pleomorphic Adenoma of the Parotid Gland: Proposal for an LMCG Classification System and an Optimized Therapeutic Algorithm. Oral Diseases. 2025. doi:10.1111/odi.70022

BibTeX
@article{Ye2025,
  author = {Ye, Qicheng and Liu, Dongrui and Huang, Lingli and Zhu, Wenya and Lu, Hao and Yang, Wenjun and Xu, Wanlin},
  title = {Recurrent Pleomorphic Adenoma of the Parotid Gland: Proposal for an LMCG Classification System and an Optimized Therapeutic Algorithm},
  journal = {Oral Diseases},
  year = {2025},
  doi = {10.1111/odi.70022}
}
Kostenlos starten →